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PRACTICE PATTERNS AND PERCEPTIONS OF THORACIC ONCOLOGY 
PROVIDERS ON TOBACCO USE AND CESSATION IN CANCER 
PATIENTS
Warren and colleagues conducted an online survey of members of the International 
Association for the Study of Lung Cancer (IASLC) regarding practice patterns, percep-
tions, and barriers to tobacco assessment and cessation in lung cancer patients. Most 
physicians taking part in the survey acknowledge the significance of quitting smoking on 
treatment outcome and as a standard part of clinical care. However, less than half of them 
actively provide cessation assistance to their patients or discuss medication options. The 
primary barriers for physicians to do so are the lack of confidence in successfully helping 
patients with tobacco cessation and concerns that patients might resist treatment. The study 
shows room for improvement in clinician training to provide cessation interventions, and in 
assessment and cessation at diagnosis and follow-up. 
Warren GW, Marshall JR, Cummings KM, et al. Practice patterns and perceptions 
of thoracic oncology providers on tobacco use and cessation in cancer patients. J Thoracic 
Oncol 2013;8:541–546.
MET AND EGFR MUTATIONS IDENTIFIED IN ALK REARRANGED 
PULMONARY ADEONCARCINOMA: MOLECULAR ANALYSIS OF 25 
ALK-POSITIVE CASES
The ALK inhibitor, Crizotinib, is approved by the FDA for treating ALK rearranged 
(ALK+) NSCLC. ALK+ is generally thought to be mutually exclusive of EGFR and KRAS 
mutations while other genetic mutations are not widely studied in ALK+ NSCLC. The 
authors therefore screened 25 ALK+ cases for mutations in 10 genes that are implicated in 
lung cancer, including EGFR, KRAS, BRAF, ERBB2, JAK2, AKT1, AKT2, KIT, MET, and 
PIK3CA. Their findings revealed additional mutations in 20% of ALK+ cases, of which 1 
case harbored EGFR del L747-S752 and 4 cases harbored c-MET mutation without c-MET 
amplification. This study demonstrated the possibility of the presence of rare EGFR muta-
tions in ALK+ NSCLC, where its clinical significance together with that of MET mutation 
is yet to be determined. In addition, the study illustrates the importance of tumor heteroge-
neity and highlights the fact that a number of presumed “acquired” mutations may simply 
represent outgrowth of pre-existing rare mutant cells.
Boland JM, Jang JS, Li J, et al. MET and EGFR mutations identified in ALK-
rearranged pulmonary adenocercinoma: molecular analysis of 25 ALK-positive cases. J 
Thoracic Oncol 2013;8:572–579.
MOLECULAR CHARACTERIZATION OF ACQUIRED RESISTANCE 
TO THE BRAF INHIBITOR DABRAFENIB IN A PATIENT WITH BRAF-
MUTANT NON-SMALL CELL LUNG CANCER
BRAF inhibitor targets mutant BRAFV600E that is found in approximately 2% of 
lung adenocarcinomas. Mechanism of acquired resistance to BRAF inhibitors have 
been extensively studied in melanoma but not in BRAF-mutant lung cancer. Rudin 
and colleagues present a case report of a 63-year-old never smoker with lung ade-
nocarcinoma, who went through therapies including carboplatin/paclitaxel, erlotinib, 
pemetrexed/bevacizumab, emcitabine, vinorelbine, and radiation, and finally enrolled 
in a phase 2 clinical trial of the selective BRAF inhibitor, dabrafenib, in patients with 
metastatic lung cancer with BRAFV600E. The patient showed partial response and an 
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8-month symptom improvement. The disease progressed and mutation profiling per-
formed on the biopsy revealed 3 new mutations in KRAS, TP53, and CDKN2A. The 
findings suggest the acquired KRASG12D mutation to be primarily responsible for the 
acquired resistance to dabrafenib in this patient because recent data supporting the 
notion that BRAFV600 inhibition leads to positive feedback and increased activity of 
and dependence on RAS, which is upstream of BRAF. The roles of TP53 and CDKN2A 
mutations in the mechanism of acquired resistance are not clear since they are not 
directly implicated in RAF signaling. This study highlights the importance of molecu-
lar characterization in progressive tumors initially responsive to therapies in gaining 
therapeutic insights and alternatives in addressing drug resistance, such as potentially 
targeting KRAS mutation in this case. 
Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to 
the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small cell lung cancer. 
J Thoracic Oncol 2013;8:541–546.
A PATIENT WITH LUNG ADENOCARCINOMA AND RET FUSION 
TREATED WITH VANDETANIB
RET fusion with KIF5B, CCDC6, or NCOA4 was recently discovered in 2% of lung 
adenocarcinoma in younger patients (<60 years), never-smokers, small primary tumor (<3 
cm), and N2 disease. Tumors with RET fusion were preclinically shown to be more sen-
sitive to vandetanib and other RET inhibitors. Gautschi and colleagues reported, for the 
first time, a patient with lung adenocarcinoma harboring RET fusion who responded to 
vandetanib treatment. Chemotherapy with carboplatin and pemetrexed initially failed to 
control the disease in this 58-year-old former smoker. However, the patient’s tumor later 
tested positive for RET and KIF5B using commercial FISH break-apart assays and was 
subsequently treated with vandetanib at the regular dose of 300 mg once daily. The patient 
showed improved symptoms and disease remission at 4 weeks. The treatment was well-
tolerated. This finding warrants future mutation testing to include RET fusions in lung 
cancer patients to guide treatment decisions. 
Gautschi O, Zander T, Keller FA, et al. A patient with lung adenocarcinoma and RET 
fusion treated with vandetanib. J Thoracic Oncol 2013;8:e43–e44.
Research Watch
TUMOR INFILTRATING IMMUNE CELLS ARE  
INDEPENDENT PREDICTORS OF RECURRENCE IN STAGE I LUNG 
ADENOCARCINOMA (ADC)
This was the first large-scale study to evaluate the prognostic factors of the tumor 
immune microenvironment in patients with stage I lung ADC. Using tissue microarray 
and immunohistochemistry, the authors demonstrated that interleukin-12 receptor β2 
(IL-12Rβ2) is expressed in normal lung epithelium and in less aggressive tumors. High 
expression of tumor IL-12Rβ2 is associated with better outcome (5-year recurrence-free 
probability). IL-7R is expressed in more aggressive tumors and is associated with worse 
outcome. The findings also revealed that FoxP3-positive regulatory T cells were abundant 
in tumor-associated stroma and created a pro-tumor environment, which may be overcome 
by high level of CD3+ lymphocytes. All the markers (IL-12Rβ2, IL-7R, and FocP3/CD3 
ratio) are independent predictors for recurrence in patients with stages IA and IB disease 
as well as for patients with tumors ≤ 2 cm. This study provides important prognostic tools 
in addition to the current staging system to stratify clinical outcome and also for future 
immunotherapeutic interventions in lung ADC.
Suzuki K, Kadota K, Sima CS, et al. Clinical Impact of Immune Microenvironment 
in Stage I Lung Adenocarcinoma: Tumor Interleukin-12 Receptor beta2 (IL-12Rbeta2), 
IL-7R, and Stromal FoxP3/CD3 Ratio Are Independent Predictors of Recurrence. J Clin 
Oncol 2013;31:490–498.
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A 12-GENE SIGNATURE PREDICTS ADjUVANT  
CHEMOTHERAPY (ACT) OUTCOME IN NON-SMALL-CELL  
LUNG CANCER (NSCLC) PATIENTS
To identify patients who will benefit from ACT in NSCLC, Tang and colleagues aimed 
to develop and validate a functional predictive gene set. Utilizing systems biology, they 
identified an 18-hub-gene set, which is implicated in tumor pathogenesis and can predict 
the prognosis of patients with early stage lung adenocarcinoma. Subsequently, a 12-gene 
signature had been derived from the integration of this 18-hub-gene set with genome-wide 
functional (RNAi) data and genetic aberration data. The 12-gene set was successfully vali-
dated in two independent datasets. This predictive signature could be therapeutically use-
ful in guiding treatment by predicting which resectable patients with NSCLC will have a 
survival benefit with ACT.
Tang H, Xiao G, Behrens C, et al. A 12-Gene Set Predicts Survival Benefits from 
Adjuvant Chemotherapy in Non-Small-Cell Lung Cancer Patients. Clin Cancer Res 2013 
[epub ahead of print]. doi:10.1158/1078-0432.ccr-12–2321.
HER-2 STATUS IN ESOPHAGEAL ADENOCARCINOMA  
(EAC) FOR PREDICTING SURVIVAL BENEFITS
This is the first report in EAC that utilized several techniques to examine HER-2 
positivity, overexpression, and gene amplification in one tissue microarray (TMA) to confirm 
their prognostic value in EAC. HER-2 gene amplification was assessed by fluorescence 
and silver-enhanced in situ hybridization (FISH and SISH) and HER-2 expression by the 
HercepTest. HER-2 positivity, overexpression, and gene amplification are fairly frequent (12 
to 18%); HER-2 positivity and gene amplification (SISH) were independently associated 
with poor survival. Based on these findings, current guidelines for HER-2 scoring in 
gastric cancer would have selected these patients for trastuzumab therapy, including those 
with IHC 1+ with gene amplification. The authors therefore recommended reevaluation 
of IHC 1+  with ISH (SISH preferred) to reduce false negative results that lead to under 
treatment of patients if treated with trastuzumab. Future clinical trials should assess whether 
these patients will benefit from trastuzumab therapy.
Prins MJD, Ruurda JP, van Diest PJ, et al. The significance of the HER-2 status in 
esophageal adenocarcinoma for survival: an immunohistochemical and an in situ hybrid-
ization study. Annals of Oncology 2013 [epub ahead of print]. doi:10.1093/annonc/mds640.
THE ROLE OF 18F-FLUORODEOxYGLUCOSE (FDG)  
POSITRON EMISSION TOMOGRAPHY (PET) IMAGING IN PATIENTS 
WITH THYMIC EPITHELIAL TUMORS (TETS)
Thomas and colleagues explored the use of [18F]-FDG PET in monitoring treatment 
and predicting outcome in TETs. The authors discovered that effective therapy leads to 
rapid decrease in [18F]-FDG uptake in patients with advanced or recurrent TETs. [18F]-FDG 
uptake was significantly higher in thymic carcinoma compared with thymoma. Another 
finding was that an early metabolic response to treatment can predict Response Evaluation 
Criteria in Solid Tumors (RECIST) response and correlates with improved progression-free 
survival. Therefore, clinically, [18F]-FDG PET could be used to monitor treatment efficacy 
and assess histological differences in advanced TETs.
Thomas A, Mena Gonzalez E, Kurdziel K, et al. 18F-Fluorodeoxyglucose positron 
emission tomography in the management of patients with thymic epithelial tumors. Clin 
Cancer Res 2013 [epub ahead of print] doi:10.1158/1078-0432.ccr-12–2929.
EPIGENETIC REPRESSION OF MIR-487B DURING  
TOBACCO-INDUCED PULMONARY CARCINOGENESIS
The authors evaluated the effect of cigarette smoke condensate (CSC) on miRNA 
alterations in human normal respiratory epithelia and lung cancer cells from smokers and 
nonsmokers using PCR-arrays. The findings showed that CSC mediates repression of miR-
487b, thereby upregulating SUZ12, BMI1, WNT5A, MYC, and KRAS, causing enhanced 
lung cancer cell proliferation and invasion in vitro, and increased metastatic potential and 
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tumorigenesis in vivo. Also, CSC-mediated repression of miR-487b coincided with DNA 
methylation and altered nucleosome positioning within this region. These observations are 
two-fold: 1) CSC mediates epigenetic repression of tumor suppressor miR-487b in pulmo-
nary carcinogenesis; and 2) they strongly suggest that CSC-mediated epigenetic repression 
of miR-487b enhances stemness phenotype of lung cancers. Further studies are warranted. 
Collectively, this study provided possible mechanism by which smoking status at diagno-
sis or during treatment affects survival of lung cancer patients, and the potential of DNA 
demethylating agents in activating miR-487b and reversing tobacco-induced lung cancer 
cell reprogramming.
Xi S, Xu H, Shan J, et al. Cigarette smoke mediates epigenetic repression of 
miR-487b during pulmonary carcinogenesis. The Journal of Clinical Investigation 
2013;123:1241–1261.
News in Brief
LUNG CANCER WILL LIkELY OVERTAkE BREAST CANCER AS THE 
NUMBER 1 CAUSE OF CANCER DEATHS AMONG EUROPEAN WOMEN
According to a new study of cancer mortality statistics in the European Union (EU) 
published in Annals of Oncology, lung cancer death rates have continued to rise (by 7%) 
since 2009 among EU women while breast cancer death rates have steadily declined (by 
7%). In 2013, breast cancer will account for the largest estimated cancer deaths in EU 
women (88,886; 15% of total), followed closely by 82,640 deaths (14% of total) from lung 
cancer. If the opposite trends in breast and lung cancer mortality rates continue in the near 
future, lung cancer may overtake breast cancer as the number 1 cause of cancer deaths 
among women in 2015.
SUVMAx: INDEPENDENT INDICATOR OF PROGRESSION-FREE  
SURVIVAL IN STAGE I NSCLC PATIENTS  
TREATED WITH RADIATION THERAPY
According to research presented at the 2013 Cancer Imaging and Radiation Therapy 
Symposium, Maximum Standardized Uptake Value (SUV
max
) may be a significant and 
clinically independent indicator of progression-free survival in stage I non-small cell lung 
cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT). Patients 
are injected with radioactive glucose and then their SUV
max
 is measured using PET/CT 
scan. Measurement of SUV in suspicious lesions could help identify early stage tumors. 
Previous studies demonstrated an association of SUV
max
 with the growth rate of tumors. 
Those tumors showing higher SUV
max
 are more likely to have characteristics of rapid 
growth, be more difficult to treat, and be more aggressive. Evaluation of SUV
max
 before 
SBRT would enable tailoring of treatment strategies, which would in turn improve outcome 
in NSCLC patients.
CT TExTURE ANALYSIS OF TUMORS AS A PROGNOSTIC  
MARkER IN PRIMARY ESOPHAGEAL CANCER
Research presented at the 2013 Cancer Imaging and Radiation Therapy Symposium 
demonstrated that CT texture analysis of primary tumors may be a potential imaging 
biomarker in localized esophageal cancer following neoadjuvant chemotherapy. Texture 
parameters (mean-grey level intensity [MGI], entropy, uniformity, kurtosis, skewness, and 
standard deviation of histogram [SDH]) were used to assess the tumoral texture analysis on 
baseline and post-treatment CT scans. The analysis involves post-processing enhancement 
of images using software that will reveal ultra-fine details of tumor features, some of which 
are associated with overall survival (OS). Increase homogeneity of primary tumor post-
treatment resulted in smaller change in skewness, which was associated with median OS of 
36.1 months versus 11.1 months. This technique would provide information on treatment 
efficacy and guidance on developing treatment plans with improved outcome.
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INCREASE CT SCAN LESION-SIZE THRESHOLD FOR LUNG CANCER
Dr. Henschke and colleagues from the International Early Lung Cancer Action 
Program (I-ELCAP) retrospectively evaluated the effect of using more restricted thresholds 
on the frequency of positive results and potential delays in diagnosis among the 21,136 
I-ELCAP participants who had baseline CT performed from 2006 to 2010. The findings, 
published in Annals of Internal Medicine, suggest that raising the nodule size threshold 
from 5 mm to 7 or 8 mm before a lung cancer work-up could generate fewer false-positive 
results (>50% decrease in both frequency of positive results and work-ups). There would 
have also been a delay in diagnosis of 5 to 6% of lung cancer cases by a maximum of 9 
months. Prospective studies are warranted to determine if this benefit of decreasing further 
work-ups outweighs the resulting delay in diagnosis of smaller cancers.
A MORE SENSITIVE MODEL THAN THE NATIONAL LUNG  
SCREENING TRIAL (NLST) CRITERIA FOR LUNG CANCER SCREENING
The NLST showed that lung cancer screening using low-dose computed tomography 
(CT) could reduce lung cancer deaths by 20%. The NLST selection criteria include an age 
between 55 and 74 years, ≥30 pack-years of smoking, and <15 years since quitting. A study 
published in The New England Journal of Medicine led by Tammemägi and colleagues 
compared the selection efficiency of their modified lung cancer risk prediction model 
(PLCO
M2012
) with NLST criteria in screening former and current smokers. In PLCO
M2012
, 
smoking predictors included smoking status, duration of smoking, smoking intensity, and 
quit time (pack-years not included). Other criteria include age, race or ethnic group, educa-
tion, body-mass index, self-reported history of chronic obstructive pulmonary disease, per-
sonal history of cancer, and family history of lung cancer. Never smokers and the predictor, 
radiography in the previous 3 years, were excluded from PLCO
M2012
.The results revealed 
that the PLCO
M2012
 model predicted the 6-year risk of lung cancer with high accuracy and 
was more efficient at selecting individuals for screening. This could make screening more 
cost-effective by potentially preventing more lung cancer mortality.
